Sign in
Taking people in United StatesNo phase

Transcranial Ultrasound Via Sonolucent Cranioplasty After Minimally Invasive Intracerebral Hemorrhage Evacuation

Key facts

Who runs it
Icahn School of Medicine at Mount Sinai
Where
New York, United StatesSee the site
Trial code
Status
Recruiting
People taking part
25 people, planned
Started
23 Sept 2022
Expected to end
Sept 2027
Type of study
Interventional
Treatments tested
  • ClearFit implant
  • transcranial ultrasonography through sonolucent cranioplasty
Record updated
5 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Presence of spontaneous supratentorial ICH ≥20 mL
  • Age ≥18 years
  • National Institute of Health Stroke Scale (NIHSS) score ≥6
  • GCS score 5-15 at presentation
  • Undergoing minimally invasive intracerebral hemorrhage evacuation with sonolucent cranioplasty or hemicraniectomy with sonolucent cranioplasty

Who cannot take part

  • Active drug or alcohol abuse that, in the opinion of the site investigator, would interfere with adherence to study enrolments
  • History of osteomyelitis
  • History of skull neoplasm
  • History of comminuted skull fractures
  • Infratentorial hemorrhage
  • Evidence of active infection indicated by fever ≥ 100.7F and/or open draining wound at the time of enrolment
  • Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 1 year
  • Coagulopathy defined as INR > 1.4, elevated aPTT, or concurrent use of direct oral anticoagulants or low molecular weight heparin at ICH onset; known hereditary or acquired hemorrhagic diathesis; coagulation factor deficiency; platelet count < 100x103cells/mm3, or known platelet dysfunction
  • Secondary cause for the ICH, such as an underlying vascular malformation (cavernous malformation, arteriovenous malformation, etc.), aneurysm, neoplasm, hemorrhagic transformation of an underlying ischemic infarct; or venous infarct
  • Midbrain extension/involvement
  • Inability to obtain consent from patient or appropriate surrogate (for patients without capacity)
  • Based on investigator's judgment, the patient does not have the necessary mental capacity to participate or is unwilling to comply with the protocol follow-up appointment schedule
  • Pre-existing DNR/DNI status

This trial is currently available in United States.

  • Mount Sinai Health SystemNew York, United StatesContact: Christopher P. Kellner, MDTaking people

About the trial

What the trial wants to find out

Postoperative rebleeding is a major limitation of surgical evacuation for intracerebral hemorrhage (ICH). While computed tomography (CT) is the standard of care for postoperative hematoma cavity monitoring, CT requires significant physical and financial costs. Studies have demonstrated varying degrees of efficacy when using transcranial ultrasound to measure ICH volume. Recently, synthetic implants for cranioplasty have been shown to be safe and sonolucent. This study aims to evaluate the ability of transcranial ultrasound with sonolucent cranioplasty (TUSC) to detect and quantify bleeding in postoperative ICH patients.

The group in the trial

  • transcranial ultrasonography through sonolucent cranioplastyTreatment being tested

    All surgical procedures and implants in this protocol are standard of care.

    Treatment: ClearFit implant and transcranial ultrasonography through sonolucent cranioplasty

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
5 May 2026